Biomedical subjects

A Boisvert

Publications and source records attributed to A Boisvert.

5 recordsLinked to original sources

PubMed1997

Use of ribotyping to distinguish Bordetella bronchiseptica isolates.

A total of 113 Bordetella bronchiseptica strains, isolated from 11 different host species worldwide, were characterized by ribotyping with restriction enzyme PvuII. Sixteen distinct ribotypes were identified, and each ribotype contained five to seven restriction fragments ranging in size from 1.8 to 5.6 kb. Approximately 88% of the swine isoaltes were identified as ribotype 3 strains. Isolates from dogs also displayed little variation; 74.1% were found to be ribotype 4 strains. Strains obtained from the remaining nine host species belonged to 15 different ribotypes. There was no association between geographic location and ribotype. The technique which we used may be useful for epidemiologic studies in which the transmission of B. bronchiseptica, both within and between species, is investigated.

Animals↗

PubMed1986

Evidence for a high and specific concentration of (Na+,K+)ATPase in the plasma membrane of the osteoclast.

During bone resorption, the osteoclast actively acidifies a limited extracellular compartment. We hypothesized that, like other cells engaged in ion transport and proton translocation, the osteoclast's membrane might be highly enriched in sodium pumps. Using monoclonal antibodies to both the alpha and the beta subunits, immunoblot analysis, and [3H]ouabain binding, we have demonstrated that the osteoclast plasma membrane is both highly and specifically enriched in (Na+,K+)ATPase, compared with other bone cells, monocytes, macrophages, and other blood and bone marrow cells. The density of binding sites on the osteoclast is equivalent to that of kidney tubule cells. This observation is consistent with the hypothesis that the (Na+,K+)ATPase plays a role in the mechanism of bone resorption, possibly coupled with secondary active calcium and/or proton transport. Monoclonal antibodies against the (Na+,K+)ATPase can therefore be used as specific markers for the osteoclast in bone and bone marrow preparations.

Animals↗

PubMed1984

Pharmacokinetics of sulfisoxazole in young and elderly subjects.

The pharmacokinetics of sulfisoxazole was studied in 6 elderly (age 63-75 years) and 7 young (age 22-37 years) healthy nonsmoking volunteers following the oral administration of 2 g of Gantrisin. The plasma levels of sulfisoxazole obtained in the postabsorption phase were higher in the elderly subjects. There was no significant variation between the two groups of volunteers in the absorption rate constant, Cmax, bioavailability, the fraction of the dose of sulfisoxazole excreted unchanged, the area under the plasma curve of the N4-acetyl conjugate formed, and in the apparent volume of distribution of the drug. The tmax value and plasma half-life of sulfisoxazole were significantly longer, and the total body and renal clearances of the drug decreased in the elderly subjects. Diminished renal function as estimated by the creatinine clearance and urinary flow may explain the slower elimination of sulfisoxazole in the elderly subjects. Therefore, advancing age should be considered as a factor in the adjustment of sulfisoxazole dosage.

Adult↗

PubMed1983

The detection of platelet antibodies using a modified platelet immunofluorescence test.

The development of sensitive immunofluorescent technics for the detection of platelet antibodies has stimulated renewed interest in the field of platelet immunology. However, the analysis of multispecific sera containing both HLA and platelet-specific antibodies requires cumbersome absorption technics and relatively large quantities of serum. In this report we describe the feasibility of screening sera from multiparous women and multitransfused patients for platelet-specific antibodies using blocking inhibition with a murine monoclonal antibody against HLA A, B, and C antigens followed by platelet immunofluorescence. Platelet immunofluorescence detected anti-A antibodies in sera from some blood group O donors. Known HLA antibodies usually were detectable by platelet immunofluorescence, but false-positive reactions occurred frequently. Analysis of sera from recipients of multiple platelet transfusions revealed that 47/78 (60.2%) were positive by platelet immunofluorescence. After blocking inhibition-persistent fluorescence was observed with 11/29 sera (37.9%), suggesting the presence of platelet-specific antibodies. Absorption studies performed on two of these sera revealed that antibody activity was removed by absorption with platelets but not lymphocytes. Platelet immunofluorescence combined with monoclonal antibody blocking inhibition proved to be a valuable tool to distinguish between HLA and platelet-specific antibodies.

ABO Blood-Group System↗

PubMed1981

Nalidixic acid-induced photodermatitis after minimal sun exposure.

More than 30 cases of bullous photodermatitis have already been associated with the administration of nalidixic acid. This reaction is reported in a 57-year-old woman whose sun exposure was minimal. Nalidixic acid-induced photoreactions generally occur in females; they affect mainly the dorsal surfaces of the hands, feet, and legs, and usually do not involve the face. Blistering is always reported, and erythema is common. Dosage regimen and duration of treatment have little influence on the onset and severity of the reaction, which is probably of allergic nature. Its duration may be long, from three to six weeks, reexposure to the sun may trigger the reappearance of blistering for several months, even in the absence of a drug rechallenge.

Female↗